CH673655A5 - - Google Patents

Download PDF

Info

Publication number: CH673655A5
Authority: CH; Switzerland
Prior art keywords: phe; boc; isobutyl; tetrafluoro; trifluoro
Prior art date: 1986-08-06

Application number

CH2936/87A

Other languages

German (de)

English (en)

Inventor

Emil Dr Pfenninger

Beat Dr Weidmann

Andre Dr Stoll

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-06

Filing date

1987-07-31

Publication date

1990-03-30

1987-07-31 Application filed by Sandoz Ag filed Critical Sandoz Ag

1990-03-30 Publication of CH673655A5 publication Critical patent/CH673655A5/de

Links

150000001875 compounds Chemical class 0.000 claims description 63
108090000765 processed proteins & peptides Proteins 0.000 claims description 27
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 22
-1 bis- (l-naphthylmethyl) acetyl Chemical group 0.000 claims description 17
229910052731 fluorine Inorganic materials 0.000 claims description 16
239000011737 fluorine Substances 0.000 claims description 16
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 15
125000000217 alkyl group Chemical group 0.000 claims description 15
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 12
239000001257 hydrogen Substances 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 10
125000000753 cycloalkyl group Chemical group 0.000 claims description 10
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
229910052801 chlorine Inorganic materials 0.000 claims description 8
239000000460 chlorine Substances 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 6
125000006239 protecting group Chemical group 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
125000003710 aryl alkyl group Chemical group 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
125000004423 acyloxy group Chemical group 0.000 claims description 3
125000004446 heteroarylalkyl group Chemical group 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
239000008024 pharmaceutical diluent Substances 0.000 claims description 2
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
125000004432 carbon atom Chemical group C* 0.000 description 57
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
239000000243 solution Substances 0.000 description 18
125000000539 amino acid group Chemical group 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 11
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
230000014759 maintenance of location Effects 0.000 description 8
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 6
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
239000003480 eluent Substances 0.000 description 6
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
229940024606 amino acid Drugs 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
150000002431 hydrogen Chemical class 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
125000002947 alkylene group Chemical group 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
125000003282 alkyl amino group Chemical group 0.000 description 3
239000012043 crude product Substances 0.000 description 3
125000002541 furyl group Chemical group 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical class 0.000 description 3
125000003884 phenylalkyl group Chemical group 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
125000001544 thienyl group Chemical group 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 2
DFVFTMTWCUHJBL-UHFFFAOYSA-N 4-azaniumyl-3-hydroxy-6-methylheptanoate Chemical compound CC(C)CC(N)C(O)CC(O)=O DFVFTMTWCUHJBL-UHFFFAOYSA-N 0.000 description 2
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108090000783 Renin Proteins 0.000 description 2
102100028255 Renin Human genes 0.000 description 2
239000002253 acid Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
125000003435 aroyl group Chemical group 0.000 description 2
238000009835 boiling Methods 0.000 description 2
MSZJEPVVQWJCIF-UHFFFAOYSA-N butylazanide Chemical compound CCCC[NH-] MSZJEPVVQWJCIF-UHFFFAOYSA-N 0.000 description 2
125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
125000000468 ketone group Chemical group 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000001175 peptic effect Effects 0.000 description 2
229910000343 potassium bisulfate Inorganic materials 0.000 description 2
229960002429 proline Drugs 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
239000002461 renin inhibitor Substances 0.000 description 2
229940086526 renin-inhibitors Drugs 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
LVKPVYNYHXIMGC-UHFFFAOYSA-N 2-ethoxycarbonyl-2-fluoro-4-methylpentanoic acid Chemical compound CCOC(=O)C(F)(C(O)=O)CC(C)C LVKPVYNYHXIMGC-UHFFFAOYSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
125000004896 2-methylbutylamino group Chemical group CC(CN*)CC 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
GRMIYECWLRTQIT-UHFFFAOYSA-N 4-amino-6-methyl-3-oxoheptanoic acid Chemical compound CC(C)CC(N)C(=O)CC(O)=O GRMIYECWLRTQIT-UHFFFAOYSA-N 0.000 description 1
BQPMNHDQFLLDNP-UHFFFAOYSA-N 5-amino-4-hydroxy-7-methyloctanoic acid Chemical compound CC(C)CC(N)C(O)CCC(O)=O BQPMNHDQFLLDNP-UHFFFAOYSA-N 0.000 description 1
HKXACQYOAPGWEE-UHFFFAOYSA-N 5-amino-6-cyclohexyl-4-hydroxyhexanoic acid Chemical compound OC(=O)CCC(O)C(N)CC1CCCCC1 HKXACQYOAPGWEE-UHFFFAOYSA-N 0.000 description 1
CJIWYHMHUUSHPI-UHFFFAOYSA-N 5-amino-6-cyclohexyl-4-oxohexanoic acid Chemical compound NC(C(CCC(=O)O)=O)CC1CCCCC1 CJIWYHMHUUSHPI-UHFFFAOYSA-N 0.000 description 1
FBTAVKSJSRZYGL-UHFFFAOYSA-N 5-amino-7-methyl-4-oxooctanoic acid Chemical compound CC(C)CC(N)C(=O)CCC(O)=O FBTAVKSJSRZYGL-UHFFFAOYSA-N 0.000 description 1
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
101000579218 Homo sapiens Renin Proteins 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-Leucine Natural products CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-Phenylalanine Natural products OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-Tyrosine Natural products OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
229930182844 L-isoleucine Natural products 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
235000019454 L-leucine Nutrition 0.000 description 1
LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001024304 Mino Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
108010011559 alanylphenylalanine Proteins 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000012491 analyte Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
TWLCEYWYILDCDA-UHFFFAOYSA-N chromium(6+) oxygen(2-) pyridine Chemical compound [O-2].[O-2].[O-2].[Cr+6].C1=CC=NC=C1.C1=CC=NC=C1 TWLCEYWYILDCDA-UHFFFAOYSA-N 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
PBKQACPFSDRXJU-UHFFFAOYSA-N diethyl 2-fluoro-2-(2-methylpropyl)propanedioate Chemical compound CCOC(=O)C(F)(CC(C)C)C(=O)OCC PBKQACPFSDRXJU-UHFFFAOYSA-N 0.000 description 1
GOWQBFVDZPZZFA-UHFFFAOYSA-N diethyl 2-fluoropropanedioate Chemical compound CCOC(=O)C(F)C(=O)OCC GOWQBFVDZPZZFA-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
125000002587 enol group Chemical group 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
108010092114 histidylphenylalanine Proteins 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
125000006316 iso-butyl amino group Chemical group [H]N(*)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
108010012058 leucyltyrosine Proteins 0.000 description 1
CEMZBWPSKYISTN-YFKPBYRVSA-N methyl (2s)-2-amino-3-methylbutanoate Chemical compound COC(=O)[C@@H](N)C(C)C CEMZBWPSKYISTN-YFKPBYRVSA-N 0.000 description 1
VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000001913 submandibular gland Anatomy 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
RQSBRFZHUKLKNO-VIFPVBQESA-N tert-butyl n-[(2s)-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound CC(C)C[C@@H](C=O)NC(=O)OC(C)(C)C RQSBRFZHUKLKNO-VIFPVBQESA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Heart & Thoracic Surgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)

CH2936/87A 1986-08-06 1987-07-31 CH673655A5 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB868619182A GB8619182D0 (en)	1986-08-06	1986-08-06	Peptides & derivatives

Publications (1)

Publication Number	Publication Date
CH673655A5 true CH673655A5 (fr)	1990-03-30

Family

ID=10602311

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH2936/87A CH673655A5 (fr)	1986-08-06	1987-07-31

Country Status (7)

Country	Link
JP (1)	JPS6348295A (fr)
BE (1)	BE1001618A4 (fr)
CH (1)	CH673655A5 (fr)
DE (1)	DE3725137A1 (fr)
FR (1)	FR2602511A1 (fr)
GB (2)	GB8619182D0 (fr)
IT (1)	IT1211681B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5071837A (en) *	1990-11-28	1991-12-10	Warner-Lambert Company	Novel renin inhibiting peptides
EP0565631B1 (fr) *	1991-01-02	1996-09-18	Merrell Pharmaceuticals Inc.	Composes antiviraux
ATE196465T1 (de) *	1993-07-08	2000-10-15	Merrell Pharma Inc	Analoge von difluoro-staton
WO1995007257A1 (fr) *	1993-09-09	1995-03-16	Merrell Pharmaceuticals Inc.	Analogues antiviraux de difluoro statone
US6114380A (en) *	1995-12-18	2000-09-05	Merrell Pharmaceuticals Inc.	Difluoro statone analogs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK356085A (da) *	1984-08-06	1986-02-07	Upjohn Co	Reninhaemmende peptid eller et farmaceutisk acceptabelt syreadditionssalt deraf
CA1341029C (fr) *	1985-02-04	2000-06-20	Michael Kolb	Inhibiteurs de la peptidase
CH672792A5 (fr) *	1985-02-19	1989-12-29	Sandoz Ag
FI865196A7 (fi) *	1985-04-19	1986-12-18	Upjohn Co	Halostatiinisubstituoituja reniini-inhibiittoreita.
HU200473B (en) *	1985-11-01	1990-06-28	Pfizer	Process for producing polypeptides containing difluorocyclostatine and pharmaceutical compositions comprising same
ES2056930T3 (es) *	1987-07-01	1994-10-16	Pfizer	Inhibidores de la renina que contienen fluor.
JPH10183253A (ja) *	1996-12-24	1998-07-14	Nisshin Steel Co Ltd	表面性状及び加工性に優れた冷延鋼板又は溶融めっき鋼板の製造方法

1986
- 1986-08-06 GB GB868619182A patent/GB8619182D0/en active Pending
1987
- 1987-07-27 BE BE8700830A patent/BE1001618A4/fr not_active IP Right Cessation
- 1987-07-27 FR FR8710662A patent/FR2602511A1/fr not_active Withdrawn
- 1987-07-28 IT IT8748235A patent/IT1211681B/it active
- 1987-07-29 DE DE19873725137 patent/DE3725137A1/de not_active Withdrawn
- 1987-07-31 CH CH2936/87A patent/CH673655A5/de not_active IP Right Cessation
- 1987-08-03 GB GB8718325A patent/GB2196958B/en not_active Expired - Lifetime
- 1987-08-05 JP JP62196151A patent/JPS6348295A/ja active Pending

Also Published As

Publication number	Publication date
JPS6348295A (ja)	1988-02-29
GB2196958A (en)	1988-05-11
FR2602511A1 (fr)	1988-02-12
GB8619182D0 (en)	1986-09-17
IT1211681B (it)	1989-11-03
BE1001618A4 (fr)	1989-12-19
GB8718325D0 (en)	1987-09-09
DE3725137A1 (de)	1988-02-11
GB2196958B (en)	1990-07-04
IT8748235A0 (it)	1987-07-28

Legal Events

Date	Code	Title	Description
1992-03-31	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE69319432T2 (de)	1998-10-29	Peptide aus Derivaten der 4-Amino-2.2.-Difluoro-3-Oxo-1.6-Hexandisäure als Wirkstoffe gegen Entzündungen
EP0119954B1 (fr)	1990-03-14	Acides 3-amino-1-benzazépine-2-one-1-alkanoiques, leur procédé de préparation, les préparations pharmaceutiques les contenant de même que leur emploi thérapeutique
DE69413085T2 (de)	1999-02-04	Immunsuppressive Aminomethylen-Peptide
EP0184550B1 (fr)	1992-03-18	Dérivés de 5-amino-4-hydroxy valérylamides
EP0089637B1 (fr)	1986-10-15	Dérivés d'amino acides bicycliques, procédé pour leur préparation, agents les contenant et leur utilisation, ainsi que des amino acides bicycliques comme produits intermédiaires et procédé pour leur préparation
EP0111873B1 (fr)	1987-10-07	Dérivés de l'acide cis, endo-aza-2 bicyclo(5.3.0)décane-carboxylique-3, procédé pour leur préparation, compositions les contenant et leur application
EP0119161B1 (fr)	1989-06-28	Dérivés de benzazocinone et benzazoninon, leur procédé de préparation, préparations pharmaceutiques contenant ces composés, et leur application thérapeutique
EP0111266A2 (fr)	1984-06-20	Tétrapeptides substitués
DE3604510A1 (de)	1986-08-21	Neue peptide und peptidderivate, ihre herstellung und verwendung und sie enthaltende pharmazeutische zubereitungen
EP0271795A2 (fr)	1988-06-22	Dérivés de l'octahydro-10-oxo-6H-pyridazo[1,2-a][112]diazépine, intermédiaires et procédé pour leur préparation ainsi que médicament les contenant
DE3885252T2 (de)	1994-02-17	Nichtpeptidische Renin-Hemmer.
EP0374098A2 (fr)	1990-06-20	Inhibiteurs de protéase rétrovirale
EP0144290A2 (fr)	1985-06-12	Dérivés éthylènediamine substitués
DE3686232T2 (de)	1993-03-25	Lactamderivate, deren herstellung und deren benutzung als hypotensive mittel.
DE69222570T2 (de)	1998-02-12	Phosphonsäurederivate, Verfahren zur Herstellung und ihre Verwendung
CH673655A5 (fr)	1990-03-30
DE69020752T2 (de)	1996-03-28	Peptide, die eine reninhemmende Aktivität besitzen, deren Herstellung und Verwendung.
DE2914793A1 (de)	1979-10-18	Pyrrolidincarboxaldehyd- und piperidincarboxaldehyd-derivate, verfahren zu ihrer herstellung und ihre verwendung als blutdrucksenkende wirkstoffe
DE69833646T2 (de)	2006-12-28	(3r)-3-amino-4-carboxybutyraldehydderivate die die il-1/beta freisetzung inhibieren
EP0203450B1 (fr)	1992-04-01	Dérivés d'amino-acides bicycliques, leur procédé de préparation, les agents les contenant et leur emploi
CH677877A5 (fr)	1991-07-15
DD272306A5 (de)	1989-10-04	Verfahren zur herstellung von peptidanalogen
DE3788888T2 (de)	1994-06-23	Perhydrothiazepin- und Perhydroazepinderivate, ihre Herstellung und ihre therapeutische Verwendung.
DE3615512A1 (de)	1987-05-14	Prolinderivate
CH651825A5 (de)	1985-10-15	Prolinderivate sowie verfahren fuer ihre herstellung.